IAMA Therapeutics Secures $12 Million in Series A Funding for Groundbreaking Epilepsy Research

IAMA Therapeutics, a pioneering clinical-stage pharmaceutical company, has successfully raised $12 million in its Series B funding round, a significant step forward in advancing its mission to tackle epilepsy and neurodevelopmental disorders. This influx of capital will primarily be directed toward the clinical development of IAMA's lead candidate, IAMA-6, a promising "best-in-class" selective NKCC1 inhibitor. IAMA-6 is uniquely designed to address a range of orphan brain disorders, particularly drug-resistant epilepsy, and has already commenced its Phase 1 clinical trial as of January 2024. The drug holds the potential to improve therapeutic outcomes for patients who have limited options due to the complexities of their conditions. In addition to the advancements with IAMA-6, the company is also committed to expanding its pipeline with innovative molecular entities aimed at targeting Cation Chloride Cotransporters, focusing on pediatric neuropsychiatric conditions. The successful completion of this Series B round is a testament to the confidence investors have in IAMA Therapeutics and its groundbreaking approach to treating challenging neurological disorders. With this funding, IAMA is well-positioned to make significant strides in its clinical trials and ultimately bring transformative therapies to patients in need, reaffirming the company’s commitment to improving quality of life across vulnerable populations.